Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
about
Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem CellsAn integrated in vitro model of perfused tumor and cardiac tissueHuman induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug developmentTranslation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision MedicineThe adverse cardiac effects of Di(2-ethylhexyl)phthalate and Bisphenol AMaturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissuesRethinking differentiation: stem cells, regeneration, and plasticityUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Concise review: microfluidic technology platforms: poised to accelerate development and translation of stem cell-derived therapiesScreening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytesMuscle on a chip: in vitro contractility assays for smooth and striated muscle.Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Human iPSC-based cardiac microphysiological system for drug screening applications.Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugsIn vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells.Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicityFutureTox II: in vitro data and in silico models for predictive toxicologySmall molecule screening in human induced pluripotent stem cell-derived terminal cell types.A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes.Biomaterial based cardiac tissue engineering and its applicationsHigh Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.Modeling the blood-brain barrier using stem cell sources.The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activityLiensinine- and Neferine-Induced Cardiotoxicity in Primary Neonatal Rat Cardiomyocytes and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Model systems for cardiovascular regenerative biology.High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.Microfluidic heart on a chip for higher throughput pharmacological studies.Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells.Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.Concise review: drug discovery in the age of the induced pluripotent stem cell.Two dimensional electrophysiological characterization of human pluripotent stem cell-derived cardiomyocyte system.Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells.
P2860
Q26750663-3B23C8EB-068D-49D4-89F1-0630E49585C0Q26822867-B403AF71-0670-46C2-A5DD-7C2AA5429504Q26995580-3E72B31B-810E-44D9-B6EE-33E495B21AB0Q28076397-9F51B2D8-F758-46F1-949F-81CFBE3E5520Q28396757-0E3A66B3-5DDF-4F83-BECC-FBECBA7F53EAQ28550738-9540A61D-A715-440B-BC14-638F274FCA36Q28656516-315AD9B1-5C55-491A-8053-E9F3FC8170E0Q30402943-B89991C4-13CA-4DF6-945A-977C08DCD20BQ30422115-71088CD7-7530-4B30-8903-8FA1B63599AEQ30558954-991A1ED3-DCCE-473A-90B6-7BA6FA1E7266Q30574106-DA6CEA2F-EF2C-4F68-B858-2266C0D2B986Q30588851-76687F3B-1DEA-4FF6-BBA5-5FDF270D2E7CQ30593372-81A08BD9-AFC3-436F-9DB3-F21279021E91Q30625616-4F97041A-E7B7-4EB4-B138-882948220100Q30629611-A458AB2F-9024-46E5-8F8A-03AED8049C59Q30656460-57FF275B-02CD-4141-80ED-82DCEFCDF2FFQ32181083-379FF545-1467-40E5-913E-5CCA5106ECE7Q33900003-15F80AAC-39D8-4B73-820A-7BFB525AF720Q34299468-472F1A3C-4C84-4DBD-B3F5-D3310D836DD7Q34980120-47E0B419-42A3-44A6-B0D6-FD9A0AF951C8Q35008383-AFF2F910-4382-421C-BEA2-184098D7AC3FQ35055252-8C85FE3B-4389-447F-AEBD-7AB6CCBD9955Q35074117-37085746-640F-4F34-BEE9-63BC9248D8F1Q35181854-2BF9CBC1-CD5E-4CBE-80FB-88081E5C5B21Q35731251-DB94211C-2361-499C-B8DA-060B788D6242Q35769756-B09849FC-22FC-46D4-AC04-B70C3D065988Q36176544-2431866D-4E29-4121-8D23-47ED516B3C45Q36184879-4AAF793F-8066-483E-B1E2-2477EEEC3EC1Q36421944-3F500228-44BD-479B-BFB0-8882A685EC29Q36588683-8944B44D-76BF-4E32-91FF-14551B01228EQ36654882-E7F0CC53-30DF-4D18-8CD3-5247E91E4C03Q36667033-DD4E02B4-126D-44CC-8D07-300818B027F4Q36933190-4AFA53FC-CDD1-438D-A995-515D864A415AQ36948480-FE532290-2DF8-47F0-9195-2B32B0037361Q37205939-6596B097-8AED-4BA8-A6EF-3E52CB6F82E0Q37542604-AD4FBB7A-7C06-43F1-9CA8-891D81A5E848Q37573646-2C869337-4DCF-4D3B-92E9-FD02762AF95CQ37680999-6EE12CFB-A2A6-443F-AE5B-6D097CF6FD24Q37683821-35F32981-E4FD-49FC-9461-92E5F58013C0Q37711224-86477BF5-4905-4EEE-8EF2-97D25EF1FA7E
P2860
Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@en
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@nl
type
label
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@en
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@nl
prefLabel
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@en
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@nl
P2093
P2860
P356
P1476
Estimating the risk of drug-in ...... m cell-derived cardiomyocytes.
@en
P2093
Eric Chiao
Jennifer D Cohen
Joshua E Babiarz
Kyle L Kolaja
Martin J Sanders
Rory M C Abrams
Sei Kameoka
P2860
P304
P356
10.1093/TOXSCI/KFR158
P577
2011-06-20T00:00:00Z